Chinese pharmaceutical company said it will invest US$100 million in development in Brazil
Chinese pharmaceutical company Sinovac announced that it will invest US$100 million in vaccine development in Brazil. The announcement was made after a meeting with the Vice President of the Republic and Minister of Development, Industry and Commerce, Geraldo Alckmin (PSB), in Beijing, China, on June 7th.
Sinovac and Fiocruz (Fundação Oswaldo Cruz) also announced their intention to cooperate in the research and development of vaccines to combat health crises. Alckmin celebrated the partnership with Fiocruz, remembering that Sinovac had previously collaborated with Brazil, more specifically with the Butantan Institute.
“I took Coronavac”said the vice-president, referring to Sinovac’s vaccine against Covid. “Science helps the world and we have to advance even further, we have to work together, which is why I welcome Sinovac’s willingness to invest in Brazil”said Alckmin.
The two institutions began negotiations to jointly strengthen their roles as official representatives of Brazil and China, in order to make access to immunization agents in Brazilian territory more equitable.
During the WHO (World Health Organization) assembly, which took place in Geneva in May, the BRICS Health ministries reaffirmed their commitment to this important initiative for global health.
During the Covid pandemic, Sinovac supplied Coronavac to the Brazilian government. At the time, 110 million doses were administered in the country. In addition to Brazil, the Chinese pharmaceutical company supplied around 3 billion vaccines to 80 countries.
#Fiocruz #Sinovac #announce #cooperation #vaccine #production